Literature DB >> 23836188

Correlations of antibiotic use and carbapenem resistance in enterobacteriaceae.

Milena McLaughlin1, M Renee Advincula, Michael Malczynski, Chao Qi, Maureen Bolon, Marc H Scheetz.   

Abstract

Epidemiological studies have shown a link between carbapenem use and resistance; however, the clinical relationship between antibiotic consumption and the epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae (CIRE) remains unclear. This study sought to analyze temporal antibiotic consumption trends for relationships with incident CIRE. In total, 310,892 days of therapy and 55 deduplicated CIRE were analyzed. When conservative corrections were applied for multiple comparisons, carbapenem class use and piperacillin-tazobactam use retained significant positive and negative relationships with the incidence of CIRE, respectively.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23836188      PMCID: PMC3811461          DOI: 10.1128/AAC.00607-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy.

Authors:  Ronald E Polk; Christina Fox; Anne Mahoney; Jim Letcavage; Conan MacDougall
Journal:  Clin Infect Dis       Date:  2007-01-22       Impact factor: 9.079

2.  Correlation between carbapenem consumption and antimicrobial resistance rates of Acinetobacter baumannii in a university-affiliated hospital in China.

Authors:  Jia Cao; Wei Song; Bing Gu; Ya-ning Mei; Jian-ping Tang; Ling Meng; Chang-qing Yang; Huijuan Wang; Hong Zhou
Journal:  J Clin Pharmacol       Date:  2013-01-24       Impact factor: 3.126

3.  Predicting gentamicin resistance from annual usage in hospital.

Authors:  H Goossens; G Ghysels; Y Van Laethem; S De Wit; J Levy; P De Mol; N Clumeck; J P Butzler; R P Wenzel
Journal:  Lancet       Date:  1986-10-04       Impact factor: 79.321

4.  First outbreak of Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in Germany.

Authors:  C Wendt; S Schütt; A H Dalpke; M Konrad; M Mieth; B Trierweiler-Hauke; M A Weigand; S Zimmermann; K Biehler; D Jonas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-03-07       Impact factor: 3.267

5.  Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.

Authors:  Moran G Goren; Shiri Navon-Venezia; Inna Chmelnitsky; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

6.  Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium.

Authors:  Simona Bratu; David Landman; Robin Haag; Rose Recco; Antonella Eramo; Maqsood Alam; John Quale
Journal:  Arch Intern Med       Date:  2005-06-27

7.  Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents.

Authors:  Simona Bratu; Pooja Tolaney; Usha Karumudi; John Quale; Mohamad Mooty; Satyen Nichani; David Landman
Journal:  J Antimicrob Chemother       Date:  2005-05-25       Impact factor: 5.790

8.  Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008.

Authors:  Elisabeth Meyer; Frank Schwab; Barbara Schroeren-Boersch; Petra Gastmeier
Journal:  Crit Care       Date:  2010-06-14       Impact factor: 9.097

9.  Differential correlation between rates of antimicrobial drug consumption and prevalence of antimicrobial resistance in a tertiary care hospital in Greece.

Authors:  Elias Iosifidis; Charalampos Antachopoulos; Maria Tsivitanidou; Aspasia Katragkou; Evagelia Farmaki; Maria Tsiakou; Theano Kyriazi; Danai Sofianou; Emmanuel Roilides
Journal:  Infect Control Hosp Epidemiol       Date:  2008-07       Impact factor: 3.254

10.  Worldwide diversity of Klebsiella pneumoniae that produce beta-lactamase blaKPC-2 gene.

Authors:  Gaelle Cuzon; Thierry Naas; HaVy Truong; Maria Virginia Villegas; Karin T Wisell; Yehuda Carmeli; Ana C Gales; Shiri Navon Venezia; John P Quinn; Patrice Nordmann
Journal:  Emerg Infect Dis       Date:  2010-09       Impact factor: 6.883

View more
  58 in total

1.  CARBapenem utilizatiON evaluation in a large community hospital (CARBON): A Quality Improvement Study.

Authors:  Jesse Janssen; Angus Kinkade; Damen Man
Journal:  Can J Hosp Pharm       Date:  2015 Jul-Aug

2.  Correlation between antibiotic consumption and resistance of bloodstream bacteria in a University Hospital in North Eastern Italy, 2008-2014.

Authors:  Marta Mascarello; Omar Simonetti; Anna Knezevich; Ludovica Ilaria Carniel; Jacopo Monticelli; Marina Busetti; Paolo Schincariol; Lucio Torelli; Roberto Luzzati
Journal:  Infection       Date:  2017-03-06       Impact factor: 3.553

3.  A Clinical Decision Tree to Predict Whether a Bacteremic Patient Is Infected With an Extended-Spectrum β-Lactamase-Producing Organism.

Authors:  Katherine E Goodman; Justin Lessler; Sara E Cosgrove; Anthony D Harris; Ebbing Lautenbach; Jennifer H Han; Aaron M Milstone; Colin J Massey; Pranita D Tamma
Journal:  Clin Infect Dis       Date:  2016-06-28       Impact factor: 9.079

4.  Implications of direct amplification for measuring antimicrobial resistance using point-of-care devices.

Authors:  M R Williams; R D Stedtfeld; H Waseem; T Stedtfeld; B Upham; W Khalife; B Etchebarne; M Hughes; J M Tiedje; S A Hashsham
Journal:  Anal Methods       Date:  2017-01-31       Impact factor: 2.896

Review 5.  Antimicrobial Stewardship: A Call to Action for Surgeons.

Authors:  Massimo Sartelli; Therese M Duane; Fausto Catena; Jeffrey M Tessier; Federico Coccolini; Lillian S Kao; Belinda De Simone; Francesco M Labricciosa; Addison K May; Luca Ansaloni; John E Mazuski
Journal:  Surg Infect (Larchmt)       Date:  2016-11-09       Impact factor: 2.150

6.  Reducing carbapenem prescribing in high-use settings: it is possible, and it is good to talk.

Authors:  Nicola Jane Fawcett
Journal:  Intern Emerg Med       Date:  2018-10-06       Impact factor: 3.397

7.  Optimizing pharmacokinetics/pharmacodynamics of β-lactam/β-lactamase inhibitor combinations against high inocula of ESBL-producing bacteria.

Authors:  Vincent H Tam; Henrietta Abodakpi; Weiqun Wang; Kimberly R Ledesma; Paul R Merlau; Katrina Chan; Rachel Altman; Truc T Tran; Michael Nikolaou; Amelia K Sofjan
Journal:  J Antimicrob Chemother       Date:  2021-01-01       Impact factor: 5.790

8.  The Culture of Carbapenem Overconsumption: Where Does It Begin? Results of a Single-Center Survey.

Authors:  Bryan T Mogle; Robert W Seabury; Zachary Jones; Christopher D Miller; Jeffrey M Steele
Journal:  Hosp Pharm       Date:  2018-05-08

9.  In Vivo Activity of WCK 4282 (High-Dose Cefepime/Tazobactam) against Serine-β-Lactamase-Producing Enterobacterales and Pseudomonas aeruginosa in the Neutropenic Murine Lung Infection Model.

Authors:  Maxwell J Lasko; Kamilia Abdelraouf; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

Review 10.  One Size Fits All? Application of Susceptible-Dose-Dependent Breakpoints to Pediatric Patients and Laboratory Reporting.

Authors:  Lindsey E Nielsen; Jeanne B Forrester; Jennifer Ellis Girotto; Aimee M Dassner; Romney Humphries
Journal:  J Clin Microbiol       Date:  2019-12-23       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.